ELIXIR MEDICAL
Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, CA, specializes in developing products that combine state-of-the-art medical devices with advanced pharmaceuticals. The company's next-generation drug-eluting stent systems are designed to optimize localized drug delivery to provide a safe and effective treatment for cardiovascular patients.
ELIXIR MEDICAL
Industry:
Health Care Medical Device Pharmaceutical
Founded:
2004-01-01
Address:
Sunnyvale, California, United States
Country:
United States
Website Url:
http://www.elixirmedical.com
Total Employee:
51+
Status:
Active
Contact:
408-636-2000
Total Funding:
5.3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
PCI Pharma Services
PCI Pharma Services is a provider of outsourced services to the global pharmaceutical market.
Spencer Health Solutions
Spencer Health Solutions is a developer of an in-home medication dispenser.
Transport Pharmaceuticals
Transport Pharmaceuticals, Inc. develops drug/device combination products for the treatment of dermal diseases. The company offers SoloVir
Current Employees Featured
Founder
Investors List
Invus
Invus investment in Series A - Elixir Medical
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-09-23 | Triple Jump Medical | Elixir Medical investment in Venture Round - Triple Jump Medical | 20 M USD |
Official Site Inspections
http://www.elixirmedical.com Semrush global rank: 9.11 M Semrush visits lastest month: 212
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Elixir Medical"
Elixir Medical - Vascular Interventions
[email protected] Elixir, Innovation for Life, DynamX, and DESyne are registered trademarks in the US and internationally for Elixir Medical Corporation. DynamX Coronary Bioadaptor System and DESyne X2 Novolimus Eluting …See details»
About Us - Elixir Medical
[email protected] Elixir, Innovation for Life, DynamX, and DESyne are registered trademarks in the US and internationally for Elixir Medical Corporation. DynamX Coronary …See details»
Elixir Medical - Crunchbase Company Profile & Funding
Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, CA, specializes in developing products that combine state-of-the-art medical …See details»
Elixir Medical Corporation - LinkedIn
Elixir Medical Corporation Medical Device Milpitas, CA 6,583 followers Elixir Medical is committed to transforming care for patients with heart and vascular disease through innovation.See details»
Elixir Medical - Craft
Elixir Medical has 5 employees across 2 locations and $5.3 m in total funding,. See insights on Elixir Medical including office locations, competitors, revenue, financials, executives, …See details»
Elixir Medical Corporation | LinkedIn
Elixir Medical is committed to transforming care of patients with heart and vascular disease through innovation. Since 2005, the company has continually sought to improve the treatment …See details»
Specialty Services - Elixir Medical Centres
Elixir Medical Services Specialty Services. The physicians at Elixir Medical Centres offer high quality in areas of specialty. Whether it’s internal medicine, endocrinology, cardiology, …See details»
Management Team - Elixir Medical
[email protected] Elixir, Innovation for Life, DynamX, and DESyne are registered trademarks in the US and internationally for Elixir Medical Corporation. DynamX Coronary Bioadaptor System and DESyne X2 Novolimus Eluting …See details»
For Patients - Edmonton Medical Clinics - Elixir Medical Centres
Prescription Fills. Please book an appointment for your refills. We cannot accept online prescription refills for some medications. Kindly note, our physicians will prescribe controlled …See details»
ESC Congress 2024 Presenting One-Year Outcomes - Elixir Medical
Aug 13, 2024 Study management is conducted in collaboration with Uppsala Clinical Research Center (UCR), a non-profit organization providing clinical research services for the …See details»
Elixir Medical to Present Late-Breaking One-Year Primary …
MILPITAS, Calif., August 13, 2024--Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced it will present one-year clinical outcomes from the …See details»
Elixir Medical Receives FDA Breakthrough Device Designation for …
MILPITAS, Calif., March 21, 2024--Elixir Medical, a developer of disruptive technologies to treat cardiovascular and peripheral disease, today announced it has been granted Breakthrough …See details»
Elixir Medical To Announce Data from Three Platforms Designed to ...
MILPITAS, Calif., April 30, 2024--Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, announced it will present long-term two-year …See details»
EuroPCR 2024: Late-breaking data demonstrate significant clinical ...
May 14, 2024 Our technologies have multiple applications across the cardiovascular space capable of delivering improved clinical outcomes for millions of patients. Visit us at …See details»
Technologies — Coronary Artery Disease - Elixir Medical
[email protected] Elixir, Innovation for Life, DynamX, and DESyne are registered trademarks in the US and internationally for Elixir Medical Corporation. DynamX Coronary …See details»
Elixir Medical To Announce Data from Three Platforms Designed to ...
Apr 30, 2024 Visit us at www.elixirmedical.com and on LinkedIn. References: 1. Iqbal et al. Final 5-Year Report of the RESOLUTE All-comers Trial. Circ Cardiovasc Interv. 2015. 2. Kufner et …See details»
Elixir Medical To Announce Late-Breaking Clinical Data at EuroPCR …
Milpitas, California, May 02, 2023 - Elixir Medical, a developer of breakthrough cardiovascular technologies, today announced that data from its BIOADAPTOR RCT randomized controlled …See details»
Clinical Evidence - Elixir Medical
Key Findings: The clinical trial met its primary endpoint of Target Lesion Failure (TLF) non-inferiority at 12 months. The novel DynamX coronary bioadaptor achieved a very low 1.8% …See details»
Elixir Medical Announces First Patient Treated in BIOADAPTOR …
Jan 13, 2021 MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the first patient has been treated in …See details»
ESC Congress 2024 - Elixir Presents Trial Data - Elixir Medical
LONDON – September 2, 2024 – Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced the INFINITY-SWEDEHEART Randomized …See details»